Patent ID: 8466111

Claim:
A method for treating myeloid leukaemia wherein the myeloid leukaemia cells express β-folate receptors in a patient in need of such treatment which comprises administering to said patient an effective amount of a cyclopenta[g]quinazoline derivative, containing an L -Glu-γ- D -Glu dipeptide group, of formula (I): wherein: R 1 is amino, C 1-4 alkyl, C 1-4 hydroxyalkyl, C 1-4 fluoroalkyl or methoxy-C 1-4 -alkyl; R 2 is hydrogren, C 1-4 alkyl, C 3-4 alkenyl, C 3-4 alkynyl, C 2-4 hydroxyalkyl C 2-4 halogenoalkyl or C 1-4 cyanoalkyl; and Ar is phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, C 1-4 alkyl and C 1-4 alkoxy; the compound (I) optionally being in the form of a pharmaceutically acceptable salt or ester.